Nalaganje...
Pathway-specific genome editing of PI3K/mTOR tumor suppressor genes reveals that PTEN loss contributes to cetuximab resistance in head and neck cancer
Cetuximab, a monoclonal antibody targeting EGFR, is a standard of care for the treatment for locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). However, despite overexpression of EGFR in over 90% of HNSCC lesions, most HNSCC patients fail to respond to cetuximab treatment....
Shranjeno v:
| izdano v: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7357849/ https://ncbi.nlm.nih.gov/pubmed/32430488 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-1036 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|